Amyloid elimination by Hsp104 and substrate-optimized variants

Hsp104 和底物优化变体消除淀粉样蛋白

基本信息

  • 批准号:
    7429951
  • 负责人:
  • 金额:
    $ 236.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-30 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

We are in dire need of innovations to combat several increasingly prevalent and inexorably lethal neurodegenerative disorders, including Alzheimer's and Parkinson's disease, which voraciously devour our social and economic resources. These disorders share a common pathogenic mechanism in which specific proteins misfold into a shared surprisingly generic conformation, termed amyloid. Amyloid fibers of diverse proteins adopt a similar `cross-β' structure, in which the strands of the β-sheets run perpendicular to the fiber axis. Further, highly cytotoxic oligomers possessing a distinct generic structure frequently accumulate prior to fibers. Although the specific protein that forms amyloid and precise localization of the deposits varies in each disease, these shared facets of amyloidogenesis bring hope that therapeutic strategies that target amyloid may have broad applications. The exceptional stability of amyloids, however, including: protease- and SDS-resistance, makes them extraordinarily difficult to clear. Indeed, they are widely perceived as intractable. Remarkably, we have found that a protein- remodeling factor from yeast, Hsp104, can rapidly disassemble amyloid fibers and oligomers comprised of the yeast prion proteins, Sup35 and Ure2. The unprecedented alacrity at which Hsp104 remodels these amyloid structures raises awareness that amyloid conformers are not intractable, and that a cellular factor capable of reversing amyloidogenesis has evolved. Curiously, although highly conserved in plants, bacteria and fungi, Hsp104 has been mysteriously lost from metazoan lineages. We hypothesize that application of Hsp104 to disease-associated amyloids may have broad therapeutic potential. Hence, we aim to: (1) annihilate amyloid fibers, oligomers and associated proteotoxicity of diverse human disease-associated proteins using Hsp104; (2) engineer or evolve substrate-optimized Hsp104 variants that attack select amyloidogenic proteins; and (3) generate Hsp104 or substrate-optimized variant therapies for animal models of amyloid-disorders. These studies will provide the foundations for new approaches to attack the devastating amyloid-disorders that plague humankind.
我们迫切需要创新,以打击几个日益普遍和 致命的神经退行性疾病,包括阿尔茨海默氏症和帕金森氏症 这些疾病贪婪地吞噬着我们的社会和经济资源。这些疾病 具有共同的致病机制,其中特定蛋白质错误折叠成共享的 令人惊讶的普通构象,称为淀粉样蛋白。不同蛋白质的淀粉样纤维 采用类似的“交叉β”结构,其中β折叠的链垂直延伸 到纤维轴。此外,具有不同的通用结构的高细胞毒性寡聚体可用于制备具有不同的通用结构的高细胞毒性寡聚体。 结构常常先于纤维积累。虽然形成这种蛋白质的 淀粉样蛋白和沉积物的精确定位在每种疾病中各不相同,这些共有的 淀粉样蛋白形成的各个方面带来了希望, 具有广泛的应用。然而,淀粉样蛋白的特殊稳定性包括: 蛋白酶和SDS抗性,使得它们非常难以清除。他们确 被广泛认为是棘手的。令人惊讶的是,我们发现一种蛋白质- 来自酵母的重塑因子Hsp 104可以快速分解淀粉样纤维, 由酵母朊病毒蛋白Sup 35和Ure 2组成的寡聚体。前所未有的 Hsp 104迅速重塑这些淀粉样结构, 淀粉样蛋白构象并不难处理,而且一种能够逆转 淀粉样变性已经进化。奇怪的是,尽管在植物中高度保守, 和真菌,Hsp 104已经神秘地从后生动物谱系中消失了。我们假设 将Hsp 104应用于疾病相关淀粉样蛋白可能具有广泛的治疗作用, 潜力因此,我们的目标是:(1)消灭淀粉样纤维,寡聚体和相关的 使用Hsp 104的多种人类疾病相关蛋白的蛋白毒性;(2)工程化 或进化出攻击选择的淀粉样蛋白的底物优化的Hsp 104变体; 和(3)产生Hsp 104或底物优化的变体疗法,用于以下动物模型: 淀粉样蛋白紊乱这些研究将为新的方法提供基础, 攻击困扰人类的毁灭性淀粉样蛋白紊乱。

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans.
  • DOI:
    10.1371/journal.pbio.1001346
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    9.8
  • 作者:
    Duennwald ML;Echeverria A;Shorter J
  • 通讯作者:
    Shorter J
The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.
  • DOI:
    10.1016/j.brainres.2012.01.016
  • 发表时间:
    2012-06-26
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    King OD;Gitler AD;Shorter J
  • 通讯作者:
    Shorter J
Applying Hsp104 to protein-misfolding disorders.
The Surprising Role of Amyloid Fibrils in HIV Infection.
  • DOI:
    10.3390/biology1010058
  • 发表时间:
    2012-05-29
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Castellano LM;Shorter J
  • 通讯作者:
    Shorter J
Emergence and natural selection of drug-resistant prions.
  • DOI:
    10.1039/c004550k
  • 发表时间:
    2010-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shorter J
  • 通讯作者:
    Shorter J
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Shorter其他文献

James Shorter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Shorter', 18)}}的其他基金

Engineering therapeutic TRIM11 disaggregases for Alzheimer's Disease-Related Dementias (ADRDs)
工程治疗 TRIM11 解聚酶治疗阿尔茨海默病相关痴呆症 (ADRD)
  • 批准号:
    10539674
  • 财政年份:
    2022
  • 资助金额:
    $ 236.25万
  • 项目类别:
Isolating small-molecule enhancers of HtrA1, an alpha-synuclein disaggregase
分离 HtrA1(一种 α-突触核蛋白解聚酶)的小分子增强子
  • 批准号:
    9374303
  • 财政年份:
    2017
  • 资助金额:
    $ 236.25万
  • 项目类别:
Exploring and enhancing Karyopherin beta-2 disaggregate activity
探索和增强核传递蛋白 beta-2 解聚活性
  • 批准号:
    9182306
  • 财政年份:
    2016
  • 资助金额:
    $ 236.25万
  • 项目类别:
Defining the mechanistic basis of a prion disaggregase
定义朊病毒解聚酶的机制基础
  • 批准号:
    8774612
  • 财政年份:
    2013
  • 资助金额:
    $ 236.25万
  • 项目类别:
Defining mechanisms of AAA+ disaggregases
AAA 解聚的定义机制
  • 批准号:
    10155900
  • 财政年份:
    2013
  • 资助金额:
    $ 236.25万
  • 项目类别:
Defining the mechanistic basis of a prion disaggregase
定义朊病毒解聚酶的机制基础
  • 批准号:
    8438661
  • 财政年份:
    2013
  • 资助金额:
    $ 236.25万
  • 项目类别:
Defining the mechanistic basis of a prion disaggregase
定义朊病毒解聚酶的机制基础
  • 批准号:
    8974843
  • 财政年份:
    2013
  • 资助金额:
    $ 236.25万
  • 项目类别:
Defining mechanisms of AAA+ disaggregases
AAA 解聚的定义机制
  • 批准号:
    10418627
  • 财政年份:
    2013
  • 资助金额:
    $ 236.25万
  • 项目类别:
Defining mechanisms of AAA+ disaggregases
AAA 解聚的定义机制
  • 批准号:
    10626853
  • 财政年份:
    2013
  • 资助金额:
    $ 236.25万
  • 项目类别:
Defining the mechanistic basis of a prion disaggregase
定义朊病毒解聚酶的机制基础
  • 批准号:
    9239262
  • 财政年份:
    2013
  • 资助金额:
    $ 236.25万
  • 项目类别:

相似海外基金

CRYSTAL STRUCTURE OF ADP COMPLEX OF ATPASE DOMAIN OF CHAPERONE HSC66
伴侣HSC66的ATP酶域ADP复合物的晶体结构
  • 批准号:
    6119556
  • 财政年份:
    1999
  • 资助金额:
    $ 236.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了